Earnings Data
Report Date
Aug 05, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
3.06Last Year’s EPS
2.35Same Quarter Last Year
Moderate Buy
Based on 5 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call reflected a generally positive tone: the company beat Q1 expectations, raised and narrowed full-year adjusted operating income and EPS guidance, demonstrated productivity-led cost improvements, and highlighted strong IKC clinical and savings performance. Material investments in technology and AI were emphasized as strategic drivers of future clinical and operational outperformance. Offsetting items included near-term pressure from higher G&A (driven by technology spend), an IKC operating loss, modest treatment declines versus prior year, ACA enrollment/mix uncertainty that could pressure revenue per treatment later in the year, and unchanged free cash flow guidance. On balance, the positive beats, guidance raise, and structural investments outweighed the near-term headwinds.Company Guidance
Beat on Adjusted Operating Income and EPS
Q1 adjusted operating income of $482 million and adjusted EPS of $2.87, with adjusted OI about $50 million ahead of forecast (roughly half from operational outperformance and half timing).
Raised Full-Year Financial Guidance
Company raised and narrowed 2026 guidance: adjusted operating income to $2.15B–$2.25B and adjusted EPS to $14.10–$15.20, driven primarily by higher volume forecast and lower patient care costs.
Volume and Utilization Improvement
Treatment volume slightly ahead of forecast; treatments per normalized day up ~40 basis points year-over-year in Q1. Full-year treatment volume guidance raised from flat to +25–50 bps (implying +50–75 bps in treatments per normalized day).
Revenue per Treatment Momentum (Q1)
Revenue per treatment increased approximately 4% year-over-year in Q1 (Joel cited ~+$17.50), with management attributing ~2/3 to normal rate/mix and ~1/3 to timing.
Cost Productivity and Patient Care Costs
Patient care cost per treatment was roughly flat to Q4, and lower-than-expected overall due to better-than-expected productivity improvements, supporting margin expansion.
IKC Clinical & Economic Performance
Integrated Kidney Care (IKC) delivered YoY improvements across 3 key CKCC measurements; company generated the highest total aggregate savings of any participant, driven by a 4.5% improvement in gross savings rate since program start.
Capital Allocation & Balance Sheet Discipline
Repurchased ~5 million shares (3M in Q1 and 2M post-quarter including Berkshire Hathaway transaction). Leverage at 3.34x consolidated EBITDA, within target range of 3.0–3.5x.
Strategic Technology Investments and AI Deployment
Investments in modernized data infrastructure and AI use cases (e.g., ScheduleHub scheduling tool and proprietary EMR) intended to improve caregiver productivity, operations and scale benefits over time.
CH:TRL Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
FAQ
When does DaVita Inc. (CH:TRL) report earnings?
DaVita Inc. (CH:TRL) is schdueled to report earning on Aug 05, 2026, After Close (Confirmed).
What is DaVita Inc. (CH:TRL) earnings time?
DaVita Inc. (CH:TRL) earnings time is at Aug 05, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of DaVita Inc. stock?
The P/E ratio of DaVita is N/A.
What is CH:TRL EPS forecast?
CH:TRL EPS forecast for the fiscal quarter 2026 (Q2) is 3.06.
